EADV: New data reinforce Sanofi’s innovative approach and leadership across immune-mediated skin diseases 24 abstracts for Dupixent, including 4 oral presentations, highlight impact of ...

We want to build a healthier, more resilient world. We turn the impossible into the possible by discovering, developing, and delivering medicines and vaccines for millions of people around the world.

Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly ...

At Sanofi, we’re proud to be premium partner of Paris 2024. Like Olympians and Paralympians, we spend every day challenging ourselves and each other to be better, go further, and to never, ever settle ...

A Million Conversations is Sanofi’s global initiative to rebuild trust in healthcare with the underrepresented. Specifically with Black and ethnic minority groups, women, people with disabilities, and ...

Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers Paris, France, and Houston, Texas, ...

Please complete this form to contact Sanofi Canada. All information you provide will be maintained in accordance with our privacy policy. We provide product information and cannot offer medical advice ...

Patients of all backgrounds need providers from all backgrounds. Our global scholarship fund is supporting individuals from diverse communities to pursue a healthcare-related career. In partnership ...

The phenomenon of smoldering-associated worsening in multiple sclerosis has been widely accepted by the medical community, yet much work is needed to fully integrate it into clinical practice.

We are dedicated to supporting the autoimmune type 1 diabetes community by exploring innovative therapies that have the potential to improve outcomes for millions of people living with the condition.

Sanofi was pleased to invite investors and analysts to participate in a webinar on September 20, 2024 to present and discuss new clinical data and results presented during the 2024 ECTRIMS meeting ...

As Premium Partner of the Paris 2024 Olympic and Paralympic Games and Official Partner of the Paris 2024 Olympic and Paralympic Torches Relays, we celebrate human achievement across various frontiers.